Gyre Therapeutics Swings to Loss as Spending Outpaces Sales Growth
Gyre Therapeutics posted a $9.9 million net loss for the first quarter, its most recent financial disclosure, after operating expenses jumped $12.1 million.
Gyre Therapeutics (GYRE) announced a board appointment in a July 16, 2026 filing, its only new disclosure since first-quarter results came out on May 7. Those first-quarter numbers remain the company's most recent financial snapshot, and they show a business that grew revenue only modestly while spending accelerated across research, marketing and a newly closed acquisition.
Revenue for the quarter reached $22.5 million, up 2% from $22.1 million a year earlier, as gains from Contiva and Etorel were mostly offset by a decline in ETUARY. That top-line growth did not carry through to the bottom line. Gyre swung to a loss from operations of $9.4 million, compared with operating income of $2.3 million in the prior-year quarter, an $11.7 million reversal tied to a $12.1 million rise in total operating expenses. Net loss came to $9.9 million, or $(0.10) a share on a GAAP basis, against net income of $3.7 million, or $0.03 a share, a year earlier. Adjusted net loss under non-GAAP measures was $4.2 million, down from adjusted net income of $2.9 million.
The expense increase was broad-based. Research and development spending more than doubled to $6.7 million from $3.1 million, with $2.0 million tied to F351's Phase 3c clinical trial and $1.1 million to new U.S. IND-enabling preclinical work. Selling and marketing costs rose 30% to $14.1 million as the company stepped up promotion for Etorel and Contiva and prepared for an F351 launch. General and administrative expense climbed 46% to $7.3 million on higher stock-based compensation and staff costs from an internal realignment. A new $2.5 million transaction-cost line item tied to the Cullgen acquisition also appeared in the quarter, and further non-recurring costs from that deal will show up in results after the quarter closed.
The Cullgen acquisition, an all-stock deal valued at roughly $300 million, closed in May 2026, adding targeted protein degraders and degrader-antibody conjugates for inflammatory diseases and cancer to Gyre's pipeline. It marks the company's first move into that modality class and follows a stretch of regulatory progress on its lead liver-fibrosis candidate: F351, or hydronidone, moved from priority review designation through NDA submission to China's Center for Drug Evaluation in March 2026 and on to formal acceptance by the National Medical Products Administration, announced May 12, 2026.
Gyre affirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million in the Q1 release, and no updated figure has surfaced in the anchor filing or in investor materials since. A separate pipeline timeline held steady as well: the company's CDK2/Cyclin E degrader, CG923308, remained on track for an IND filing in the first quarter of 2027 across investor presentations dated May 14 and June 2, 2026.
Total cash, including short-term deposits and long-term certificates of deposit, rose 4% to $79.2 million as of March 31 from $75.9 million at year-end 2025, helped by stronger customer collections and lower tax payments. That cash position sits alongside the newly issued Cullgen transaction costs and the widening operating loss as factors likely to shape spending through the rest of the year, though Gyre has not updated guidance to reflect the deal's closing.